4.7 Article

UV activation of polymeric high aspect ratio microstructures: ramifications in antibody surface loading for circulating tumor cell selection

Journal

LAB ON A CHIP
Volume 14, Issue 1, Pages 106-117

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/c3lc50618e

Keywords

-

Funding

  1. UNC's the University Cancer Research Fund (UCRF)
  2. U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-SC0001011]
  3. UNC Solar Energy Research Center (SERC)
  4. US Department of Energy - Office of Energy Efficiency & Renewable Energy [DE-EE0003188]

Ask authors/readers for more resources

The need to activate thermoplastic surfaces using robust and efficient methods has been driven by the fact that replication techniques can be used to produce microfluidic devices in a high production mode and at low cost, making polymer microfluidics invaluable for in vitro diagnostics, such as circulating tumor cell (CTC) analysis, where device disposability is critical to mitigate artifacts associated with sample carryover. Modifying the surface chemistry of thermoplastic devices through activation techniques can be used to increase the wettability of the surface or to produce functional scaffolds to allow for the covalent attachment of biologics, such as antibodies for CTC recognition. Extensive surface characterization tools were used to investigate UV activation of various surfaces to produce uniform and high surface coverage of functional groups, such as carboxylic acids in microchannels of different aspect ratios. We found that the efficiency of the UV activation process is highly dependent on the microchannel aspect ratio and the identity of the thermoplastic substrate. Colorimetric assays and fluorescence imaging of UV-activated microchannels following EDC/NHS coupling of Cy3-labeled oligonucleotides indicated that UV-activation of a PMMA microchannel with an aspect ratio of similar to 3 was significantly less efficient toward the bottom of the channel compared to the upper sections. This effect was a consequence of the bulk polymer's damping of the modifying UV radiation due to absorption artifacts. In contrast, this effect was less pronounced for COC. Moreover, we observed that after thermal fusion bonding of the device's cover plate to the substrate, many of the generated functional groups buried into the bulk rendering them inaccessible. The propensity of this surface reorganization was found to be higher for PMMA compared to COC. As an example of the effects of material and microchannel aspect ratios on device functionality, thermoplastic devices for the selection of CTCs from whole blood were evaluated, which required the immobilization of monoclonal antibodies to channel walls. From our results, we concluded the CTC yield and purity of isolated CTCs were dependent on the substrate material with COC producing the highest clinical yields for CTCs as well as better purities compared to PMMA.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Critical Care Medicine

Recent Trends in Admission Diagnosis and Related Mortality in the Medically Critically Ill

Nicholas E. Ingraham, Victor Vakayil, Kathryn M. Pendleton, Alexandria J. Robbins, Rebecca L. Freese, Elise F. Palzer, Anthony Charles, R. Adams Dudley, Christopher J. Tignanelli

Summary: The study found that ICU mortality rate remained unchanged over the years, but there were changes in disease burden and outcomes. Certain disease groups such as toxicology and hematologic/oncologic cases increased, while others like gastrointestinal and pulmonary cases decreased. Overall risk-adjusted in-hospital mortality rate did not change, but the length of stay in the ICU decreased over the study period.

JOURNAL OF INTENSIVE CARE MEDICINE (2022)

Article Surgery

Predicting outcomes after traumatic brain injury: A novel hospital prediction model for a patient reported outcome

Rachel S. Morris, Juan F. Figueroa, Courtney J. Pokrzywa, Jason K. Barber, Nancy R. Temkin, Carisa Bergner, Basil S. Karam, Patrick Murphy, Lindsay D. Nelson, Purushottam Laud, Zara Cooper, Marc de Moya, Colleen Trevino, Christopher J. Tignanelli, Terri A. deRoon-Cassini

Summary: This study aimed to develop a model for predicting the quality of life in hospitalized adults with Traumatic brain injuries (TBIs). By analyzing the dataset, researchers found that private insurance, higher Glasgow Coma Scale (GCS) scores, and fewer comorbidities were associated with better quality of life. They developed a model (TBI-PRO) for predicting the quality of life scores at different time points and concluded that the model adequately estimates long-term outcomes in patients with TBI.

AMERICAN JOURNAL OF SURGERY (2022)

Article Rehabilitation

Predictors of Postacute Sequelae of COVID-19 Development and Rehabilitation: A Retrospective Study

Nermine Abdelwahab, Nicholas E. Ingraham, Nguyen Nguyen, Lianne Siegel, Greg Silverman, Himanshu Shekhar Sahoo, Serguei Pakhomov, Leslie R. Morse, Joanne Billings, Michael G. Usher, Tanya E. Melnik, Christopher J. Tignanelli, Farha Ikramuddin

Summary: This study examined the frequency of postacute sequelae of SARS-CoV-2 (PASC) and factors associated with rehabilitation utilization. The results showed that patients with PASC had higher utilization of rehabilitation services and factors such as younger age, comorbidities, and male sex were significantly associated with rehabilitation utilization.

ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION (2022)

Article Medicine, General & Internal

Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury A Randomized Clinical Trial

Michael A. Puskarich, Nicholas E. Ingraham, Lisa H. Merck, Brian E. Driver, David A. Wacker, Lauren Page Black, Alan E. Jones, Courtney Fletcher, Andrew M. South, Thomas A. Murray, Christopher Lewandowski, Joseph Farhat, Justin L. Benoit, Michelle H. Biros, Kartik Cherabuddi, Jeffrey G. Chipman, Timothy W. Schacker, Faheem W. Guirgis, Helen T. Voelker, Joseph S. Koopmeiners, Christopher J. Tignanelli

Summary: This study found that oral administration of losartan did not improve the PaO2:FiO(2) ratio at 7 days in hospitalized patients with COVID-19 and acute lung injury. The use of losartan also did not improve secondary clinical outcomes and resulted in fewer vasopressor-free days compared to placebo.

JAMA NETWORK OPEN (2022)

Article Medicine, General & Internal

Comparison of Outcomes and Process of Care for Patients Treated at Hospitals Dedicated for COVID-19 Care vs Other Hospitals

Zachary R. Bergman, Michael Usher, Andrew Olson, Jeffrey G. Chipman, Melissa E. Brunsvold, Greg Beilman, Christopher Tignanelli, Elizabeth R. Lusczek

Summary: This study analyzed the relationship between treatment at COVID-19-dedicated hospitals and mortality rate and complications. The results showed that patients treated at COVID-19-dedicated hospitals had lower in-hospital mortality and lower rate of complications.

JAMA NETWORK OPEN (2022)

Editorial Material Surgery

Postoperative Intensive Care Unit Overtriage An Application of Machine Learning

Emma K. Jones, Christopher J. Tignanelli

ANNALS OF SURGERY (2023)

Article Immunology

Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial

David R. Boulware, Thomas A. Murray, Jennifer L. Proper, Christopher J. Tignanelli, John B. Buse, David M. Liebovitz, Jacinda M. Nicklas, Kenneth Cohen, Michael A. Puskarich, Hrishikesh K. Belani, Lianne K. Siegel, Nichole R. Klatt, David J. Odde, Amy B. Karger, Nicholas E. Ingraham, Katrina M. Hartman, Via Rao, Aubrey A. Hagen, Barkha Patel, Sarah L. Fenno, Nandini Avula, Neha Reddy, Spencer M. Erickson, Sarah Lindberg, Regina Fricton, Samuel Lee, Adnin Zaman, Hanna G. Saveraid, Walker J. Tordsen, Matthew F. Pullen, Nancy E. Sherwood, Jared D. Huling, Carolyn T. Bramante

Summary: SARS-CoV-2 vaccine-boosted participants experienced the least severe symptoms during COVID-19, and their symptoms improved the fastest over time. Vaccination against SARS-CoV-2 was found to be associated with reduced symptom severity in a sample of low to moderate risk adults enrolled in an outpatient COVID-19 treatment trial. Booster shots further reduced symptom severity.

CLINICAL INFECTIOUS DISEASES (2023)

Editorial Material Surgery

Invited Commentary Postoperative Artificial Intelligence Model for ICU Triage

Thomas F. Byrd, Jason Ho, Christopher J. Tignanelli

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2023)

Article Chemistry, Analytical

Assessing Breast Cancer Molecular Subtypes Using Extracellular Vesicles? mRNA

Mengjia Hu, Virginia Brown, Joshua M. Jackson, Harshani Wijerathne, Harsh Pathak, Devin C. Koestler, Emily Nissen, Mateusz L. Hupert, Rolf Muller, Andrew K. Godwin, Malgorzata A. Witek, Steven A. Soper

Summary: Extracellular vesicles (EVs) have the potential to be used as a minimally invasive liquid biopsy marker for precision medicine, as they carry RNA cargo associated with the cell-of-origin. Researchers have developed an EV microfluidic affinity purification (EV-MAP) chip, made from plastic for high-scale production, which can isolate EV subpopulations. They demonstrated the utility of this chip in molecular subtyping breast cancer patients, isolating two subpopulations of EVs that better recapitulate the tumor microenvironment. The EV-MAP provided high recovery and specificity based on exosomal mRNA and PCR results, and the EV subpopulations showed potential for prognostication using the PAM50 test.

ANALYTICAL CHEMISTRY (2023)

Article Infectious Diseases

Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT) : a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial

Carolyn T. Bramante, John B. Buse, David M. Liebovitz, Jacinda M. Nicklas, Michael A. Puskarich, Ken Cohen, Hrishikesh K. Belani, Blake J. Anderson, Jared D. Huling, Christopher J. Tignanelli, Jennifer L. Thompson, Matthew Pullen, Esteban Lemus Wirtz, Lianne K. Siegel, Jennifer L. Proper, David J. Odde, Nichole R. Klatt, Nancy E. Sherwood, Sarah M. Lindberg, Amy B. Karger, Kenneth B. Beckman, Spencer M. Erickson, Sarah L. Fenno, Katrina M. Hartman, Michael R. Rose, Tanvi Mehta, Barkha Patel, Gwendolyn Griffiths, Neeta S. Bhat, Thomas A. Murray

Summary: This study aimed to evaluate the potential of outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine to reduce the risk of long COVID. The findings showed that metformin treatment was associated with a 41% reduction in the incidence of long COVID compared to placebo, while ivermectin and fluvoxamine did not have the same effect.

LANCET INFECTIOUS DISEASES (2023)

Article Biochemistry & Molecular Biology

Developing A Baseline Metabolomic Signature Associated with COVID-19 Severity: Insights from Prospective Trials Encompassing 13 U.S. Centers

Kaifeng Yang, Zhiyu Kang, Weihua Guan, Sahar Lotfi-Emran, Zachary J. Mayer, Candace R. Guerrero, Brian T. Steffen, Michael A. Puskarich, Christopher J. Tignanelli, Elizabeth Lusczek, Sandra E. Safo

Summary: Metabolic disease is a significant risk factor for severe COVID-19 infection. This study aimed to characterize metabolic features that predict severe COVID-19 and define a novel baseline metabolomic signature. The results showed that metabolites related to lipid metabolism efficiently discriminated between mild and moderate/severe disease, and pathways related to amino acids were significantly enriched in severe disease. The mitogen-activated protein kinase kinase 5 (MAP2K5) regulator was differentially activated between groups, suggesting further investigation as a potential therapeutic pathway.

METABOLITES (2023)

Article Medicine, General & Internal

Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19

C. T. Bramante, J. D. Huling, C. J. Tignanelli, J. B. Buse, D. M. Liebovitz, J. M. Nicklas, K. Cohen, M. A. Puskarich, H. K. Belani, J. L. Proper, L. K. Siegel, N. R. Klatt, D. J. Odde, D. G. Luke, B. Anderson, A. B. Karger, N. E. Ingraham, K. M. Hartman, V Rao, A. A. Hagen, B. Patel, S. L. Fenno, N. Avula, N. Reddy, S. M. Erickson, S. Lindberg, R. Fricton, S. Lee, A. Zaman, H. G. Saveraid, W. J. Tordsen, M. F. Pullen, M. Biros, N. E. Sherwood, J. L. Thompson, D. R. Boulware, T. A. Murray

Summary: This study evaluates the effectiveness of metformin, ivermectin, and fluvoxamine in preventing severe Covid-19. The results show that none of these drugs can prevent hypoxemia, emergency department visits, hospitalization, or death associated with Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Health Care Sciences & Services

Federated learning for preserving data privacy in collaborative healthcare research

Tyler J. Loftus, Matthew M. Ruppert, Benjamin Shickel, Tezcan Ozrazgat-Baslanti, Jeremy A. Balch, Philip A. Efron, Gilbert R. Upchurch, Parisa Rashidi, Christopher Tignanelli, Jiang Bian, Azra Bihorac

Summary: In healthcare AI applications, maintaining generalizability, external validity, and reproducibility is crucial. Traditional approaches of sharing patient data can compromise data privacy and security. Federated learning techniques offer an alternative by sharing knowledge instead of data, preserving both data privacy and availability.

DIGITAL HEALTH (2022)

Article Computer Science, Artificial Intelligence

Performance of a Chest Radiograph AI Diagnostic Tool for COVID-19: A Prospective Observational Study

Ju Sun, Le Peng, Taihui Li, Dyah Adila, Zach Zaiman, Genevieve B. Melton-Meaux, Nicholas E. Ingraham, Eric Murray, Daniel Boley, Sean Switzer, John L. Burns, Kun Huang, Tadashi Allen, Scott D. Steenburg, Judy Wawira Gichoya, Erich Kummerfeld, Christopher J. Tignanelli

Summary: A prospective observational study was conducted across 12 U.S. hospitals to evaluate the real-time performance of an interpretable AI model in detecting COVID-19 on chest radiographs. The study found that the accuracy of the model still has room for improvement compared to radiologist predictions.

RADIOLOGY-ARTIFICIAL INTELLIGENCE (2022)

Article Medicine, General & Internal

Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19

C. T. Bramante, J. D. Huling, C. J. Tignanelli, J. B. Buse, D. M. Liebovitz, J. M. Nicklas, K. Cohen, M. A. Puskarich, H. K. Belani, J. L. Proper, L. K. Siegel, N. R. Klatt, D. J. Odde, D. G. Luke, B. Anderson, A. B. Karger, N. E. Ingraham, K. M. Hartman, V Rao, A. A. Hagen, B. Patel, S. L. Fenno, N. Avula, N. Reddy, S. M. Erickson, S. Lindberg, R. Fricton, S. Lee, A. Zaman, H. G. Saveraid, W. J. Tordsen, M. F. Pullen, M. Biros, N. E. Sherwood, J. L. Thompson, D. R. Boulware, T. A. Murray

Summary: This study evaluated the effectiveness of three repurposed drugs in preventing severe SARS-CoV-2 infection in nonhospitalized adults, but none of these medications were found to prevent hypoxemia, emergency department visits, hospitalization or death associated with Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

No Data Available